Loading...
•
Jun 30, 2021
Supernus Q2 2021 Earnings Report
Reported a 12% revenue increase compared to 2020, driven by net product sales.
Key Takeaways
Supernus Pharmaceuticals reported a revenue increase of 12% compared to 2020. The company launched Qelbree for pediatric ADHD and submitted an sNDA for adult ADHD. Operating earnings decreased compared to the same period last year.
Total revenues for Q2 2021 were $141.3 million, a 12% increase compared to 2020.
Net product sales for Q2 2021 were $138.6 million, a 12% increase compared to 2020.
Qelbree was launched in the U.S. for pediatric ADHD at the end of May 2021, with net product sales of $0.3 million in Q2 2021.
An sNDA for Qelbree for adult ADHD was submitted to the FDA.
Revenue by Segment
Forward Guidance
Supernus Pharmaceuticals provided full year 2021 financial guidance, including total revenues between $550 and $580 million and operating earnings between $70 and $90 million.
Positive Outlook
- Total revenues between $550 and $580 million.
- Combined R&D and SG&A expenses between $380 and $410 million.
- Operating earnings between $70 and $90 million.
- Amortization of intangible assets of $24 million.
- Effective tax rate between 28% and 31%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...